Chicago, IL & San Diego, CA – Receptor.AI, a TechBio company specializing in AI-driven drug discovery, recently showcased its latest advancements at two significant industry gatherings: the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago and the BIO International Convention in San Diego.

‍

Engaging with Oncology Leaders at ASCO 2024

From May 31 to June 4, the ASCO 2024 Annual Meeting hosted approximately 50,000 participants from across the globe, making it one of the largest gatherings in oncology. Receptor.AI took this opportunity to engage with leading minds in cancer research and treatment.

Our CEO, Dr. Alan Nafiiev, engaged extensively with oncology professionals, sharing insights and exploring the latest in AI-driven drug discovery. The discussions and connections made at ASCO 2024 have reinforced our commitment to advancing cancer research, with an emphasis on applying artificial intelligence to develop new therapeutic strategies.

Showcasing AI Innovations at BIO International Convention

Following the success at ASCO, Receptor.AI continued its presence at the BIO International Convention held from June 3-6 in San Diego. The conference brought together industry professionals to discuss the latest trends and innovations in drug discovery.

On behalf of Receptor.AI, Dr. Alan Nafiiev presented our AI model for predicting Protein-Protein Interactions (PPIs) using a template-agnostic approach. This model demonstrates superior performance, especially in scenarios where structural templates of the complexes are absent—a challenge that previous technologies, including AlphaFold3, could not overcome.

The launch of this model at BIO 2024 received strong interest, reflecting the industry’s readiness for innovative solutions that can enhance current drug discovery pipelines. As a result, several new projects are now being initiated to apply our PPI capabilities in preclinical drug development.

You can learn more about our new PPI workflow via the link.

‍

Looking Forward

These two conferences have helped strengthen Receptor.AI’s position within the AI biotech landscape and opened new opportunities for collaboration in drug discovery. The insights gained and the connections made are invaluable as we continue to drive progress in the AI-driven drug discovery design.

"We are grateful for the reception and the thoughtful discussions we’ve had at both ASCO and BIO," said Dr. Nafiiev. "These interactions motivate us to keep advancing AI methods that support a deeper understanding of disease biology and drug discovery."

Receptor.AI looks forward to maintaining this momentum at future events and continuing to share progress with the biotech community.

‍

Stay tuned for more updates as we launch new projects and further apply our platform to drug discovery.

‍

Read more about our new template-agnostic PPI workflow.